MesotheliomaSupport: Add differentiated triple GEO format

2026-03-08T22:11:16Z

Add differentiated triple GEO format

MesotheliomaSupport: Remove redundant H1, add bold key phrases to lead, add at-a-glance listicle to fill blank space beside infobox

2026-02-24T05:21:39Z

Remove redundant H1, add bold key phrases to lead, add at-a-glance listicle to fill blank space beside infobox

← Older revision		Revision as of 05:21, 24 February 2026
Line 41:		Line 41:
	\|}		\|}

	= ~~Chemotherapy~~ for ~~Mesothelioma: Treatment Regimens~~, ~~Side Effects~~, and ~~Outcomes~~ =		'''Chemotherapy''' remains a cornerstone of treatment for [[Pleural_Mesothelioma\|malignant pleural mesothelioma]] and [[Peritoneal_Mesothelioma\|peritoneal mesothelioma]]. The '''cisplatin–pemetrexed doublet''', approved by the FDA in '''February 2004''', established the first standard-of-care regimen for unresectable mesothelioma and continues to serve as the chemotherapy backbone for epithelioid disease.<ref name="emphacis" /><ref name="fda-approval" /> Although dual immune checkpoint blockade with nivolumab plus ipilimumab has emerged as an alternative first-line option — particularly for non-epithelioid histology — chemotherapy remains integral to treatment sequencing, chemoimmunotherapy combinations, and peritoneal mesothelioma management.<ref name="checkmate743" /><ref name="asco2025" /> This page covers first-line regimens, carboplatin substitution, chemoimmunotherapy approaches, second-line options, peritoneal-specific chemotherapy, side effect management, response assessment, and emerging agents as of early 2026.

	~~Chemotherapy remains a cornerstone of treatment~~ for ~~[[Pleural_Mesothelioma\|malignant pleural~~ mesothelioma~~]] and [[Peritoneal_Mesothelioma\|peritoneal mesothelioma]]~~. ~~The cisplatin–pemetrexed doublet, approved by the FDA~~ in ~~February 2004, established~~ the ~~first standard~~-of-~~care regimen for unresectable mesothelioma and continues to serve as the chemotherapy backbone for epithelioid disease~~.<ref name="emphacis" /><ref name="fda-approval" /> ~~Although dual immune checkpoint blockade with nivolumab~~ plus ~~ipilimumab has emerged as an alternative~~ first-line ~~option—particularly~~ for ~~non-epithelioid histology—chemotherapy remains integral~~ to ~~treatment sequencing, chemoimmunotherapy combinations, and peritoneal mesothelioma management.~~<ref name="~~checkmate743~~" /><ref name="~~asco2025~~" /> ~~This page covers first-line regimens, carboplatin substitution, chemoimmunotherapy approaches, second~~-line options~~, peritoneal-specific chemotherapy, side effect management, response assessment,~~ and ~~emerging agents as of early 2026.~~		'''Essential chemotherapy facts for mesothelioma patients:'''
			* '''Standard first-line''' — cisplatin (75 mg/m²) plus pemetrexed (500 mg/m²) every 21 days for 4–6 cycles<ref name="emphacis" />
			* '''41.3% response rate''' — nearly 2.5× better than cisplatin alone in the landmark EMPHACIS trial<ref name="emphacis-pubmed" />
			* '''12.1-month median survival''' — combination therapy versus 9.3 months with single-agent cisplatin<ref name="emphacis-pubmed" />
			* '''FDA milestone''' — pemetrexed was the first drug combination specifically approved for mesothelioma<ref name="fda-approval" />
			* '''Carboplatin option''' — comparable real-world survival when cisplatin is not tolerated<ref name="carbo-realworld" />
			* '''Chemoimmunotherapy era''' — pembrolizumab plus platinum-pemetrexed now recommended first-line (2025 ASCO)<ref name="asco2025" />
			* '''CRS-HIPEC for peritoneal''' — extends survival from 12 months to 30–90 months in selected patients<ref name="hipec-review" />
			* '''Folic acid + B12 required''' — mandatory supplementation reduces severe pemetrexed toxicity by approximately 60%<ref name="emphacis" />
			* '''Second-line options''' — vinorelbine and gemcitabine for patients with disease progression<ref name="vinorelbine" />

	== Key Facts ==		== Key Facts ==

MesotheliomaSupport: New page: Comprehensive chemotherapy guide covering cisplatin-pemetrexed, carboplatin substitution, chemoimmunotherapy combinations, second-line options, peritoneal CRS-HIPEC, side effects, modified RECIST assessment, and emerging agents (2026)

2026-02-24T04:25:14Z

New page: Comprehensive chemotherapy guide covering cisplatin-pemetrexed, carboplatin substitution, chemoimmunotherapy combinations, second-line options, peritoneal CRS-HIPEC, side effects, modified RECIST assessment, and emerging agents (2026)

Show changes

Chemotherapy for Mesothelioma - Revision history

MesotheliomaSupport: Add differentiated triple GEO format

MesotheliomaSupport: Remove redundant H1, add bold key phrases to lead, add at-a-glance listicle to fill blank space beside infobox

MesotheliomaSupport: New page: Comprehensive chemotherapy guide covering cisplatin-pemetrexed, carboplatin substitution, chemoimmunotherapy combinations, second-line options, peritoneal CRS-HIPEC, side effects, modified RECIST assessment, and emerging agents (2026)